Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-27-013

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

Open. Closes November 2, 2028.

Posted
March 18, 2026
Close date
November 2, 2028
Activity codes
U24
Institutes taking part
NHLBI

Read the notice on Grants.gov

The notices it replaced

  1. Reissues: PAR-22-193 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
  2. 2 steps back: PAR-19-330 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
  3. 3 steps back: PAR-18-410 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
  4. 4 steps back: PAR-16-301 Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)

Who won it before

54 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $40,007,224 in first-year total cost, median $674,171.

Most frequent study sections

  1. Clinical Trials Review Study Section[CLTR (MA)]19
  2. Clinical Trials Review Study Section[CLTR (JA)]13
  3. Clinical Trials Review Study Section[CLTR (OA)]7
  4. Special Emphasis Panel[ZHL1 CSR-Z (J1)]3
  5. Special Emphasis Panel[ZHL1 CSR-H (F1)]2

Most frequent institutions

  1. DUKE UNIVERSITY7
  2. RESEARCH TRIANGLE INSTITUTE5
  3. UNIVERSITY OF PITTSBURGH AT PITTSBURGH4
  4. JOHNS HOPKINS UNIVERSITY3
  5. MEDICAL UNIVERSITY OF SOUTH CAROLINA3
Competing awards under PAR-27-013 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
20252/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)1U24HL180994-01 · under PAR-22-193SPINO, CATHERINE AUNIVERSITY OF MICHIGAN AT ANN ARBOR, MI$936,858ZHL1
2025ASTRO: Adjuvant STeroid Outcomes in idiopathic subglottic stenosis: A randomized trial1U24HL173399-01A1 · under PAR-22-193HANLEY, DANIEL FYENOKYAN, GAYANEJOHNS HOPKINS UNIVERSITY, MD$921,009CLTR
2025(2/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): DCC1U24HL176626-01A1 · under PAR-22-193GLYNN, ROBERT JBRIGHAM AND WOMEN'S HOSPITAL, MA$862,130CLTR
20252/2- Randomized comparison of the Outcomes of single vs Multiple Arterial grafts trial in Women (ROMA:Women)1U24HL169562-01A1 · under PAR-22-193BAGIELLA, EMILIAGELIJNS, ANNE CHRISTINEICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY$770,844CLTR
20252/2 WIN Ratio Analysis to Determine a Strategy of Non-Invasive SUpport for Respiratory Failure in the EmeRgency Department (WINDSURFER)1U24HL175258-01A1 · under PAR-22-193DURKALSKI, VALERIE LWEI, LAIMEDICAL UNIVERSITY OF SOUTH CAROLINA, SC$688,047ZHL1
20252/2 Women's Aneurysm Research: Repair Immediately Or Routine Surveillance: WARRIORS trial1U24HL181192-01 · under PAR-22-193BECK, ADAM WSZYCHOWSKI, JEFF MUNIVERSITY OF ALABAMA AT BIRMINGHAM, AL$318,167CLTR
20242/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)1U24HL173304-01 · under PAR-22-193DAS, ABHIKRESEARCH TRIANGLE INSTITUTE, NC$1,397,921CLTR
20242/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - DCC Resubmission1U24HL166580-01A1 · under PAR-22-193DAS, ABHIKRESEARCH TRIANGLE INSTITUTE, NC$1,172,434CLTR
20242/2 Circulatory Support in Pediatric Heart Failure Patients Using the Jarvik 2015 LVAD: A Pivotal Trial1U24HL163316-01A1 · under PAR-19-330MAGNAVITA, ASHLEYZAK, VICTORNEW ENGLAND RESEARCH INSTITUTES, INC., DE$1,061,181ZHL1
20241/2 Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia - The "NONO trial" - a pragmatic, multi-center, de-implementation, stepped-wedge, cluster-randomized trial1U24HL166769-01A1 · under PAR-22-193HARTING, MATTHEW TIHENPEDROZA, CLAUDIAYAMAL, JOSE-MIGUELUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX$743,657CLTR
20242/2 Data Coordinating Center for the Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction Study (SPIRRIT-EX)1U24HL173568-01 · under PAR-22-193ANSTROM, KEVIN JCHAKRABORTY, HRISHIKESHDUKE UNIVERSITY, NC$703,312ZHL1
20242/2 Improving Mobility After Revascularization in Peripheral Artery Disease: The IMPACT PAD Trial1U24HL169563-01A1 · under PAR-22-193AMBROSIUS, WALTER TWAKE FOREST UNIVERSITY HEALTH SCIENCES, NC$699,396CLTR
20242/2 Low dose colchicine in pAtients with peripheral artery DiseasE to assess residual vascular risk (LEADER-PAD)1U24HL171356-01A1 · under PAR-22-193BANGDIWALA, SHRIKANT IBOSCH, JACKIEEIKELBOOM, JOHNVEMULAPALLI, SREEKANTHDUKE UNIVERSITY, NC$610,248ZHL1
20242/2 Self-directed mobile adaptive coping skills intervention to improve psychological distress symptoms among cardiorespiratory failure survivors: the Blueprint RCT1U24HL168491-01A1 · under PAR-22-193HOUGH, CATHERINE LEEMORRIS, CYNTHIA DOREGON HEALTH & SCIENCE UNIVERSITY, OR$555,597CLTR
2024Master - 2/2 Empaglifozin To Improve Right Ventricular Function in Pulmonary Arterial Hypertension1U24HL175028-01 · under PAR-22-193GASSMAN, JENNIFER JCLEVELAND CLINIC LERNER COM-CWRU, OH$371,492CLTR
20232/2 REPRIEVE Extension for Trial Completion1U24HL164284-01 · under PAR-19-330LU, MICHAEL TSE-YINRIBAUDO, HEATHER JANEMASSACHUSETTS GENERAL HOSPITAL, MA$1,243,585ZHL1
20232/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)1U24HL166784-01A1 · under PAR-22-193BAEDORF KASSIS, ELIASHOULE, TIMOTHY TBETH ISRAEL DEACONESS MEDICAL CENTER, MA$1,175,434CLTR
20232/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)1U24HL165029-01A1 · under PAR-19-330O'BRIEN, SEAN MVEMULAPALLI, SREEKANTHDUKE UNIVERSITY, NC$820,509ZHL1
20232/2 CORD-CHD: Clamp OR Delay among neonates with Congenital Heart Disease1U24HL166799-01 · under PAR-19-330EVANS, SCOTTRICE, MADELINE MURGUIASANDOVAL, GRECIO JANGEORGE WASHINGTON UNIVERSITY, DC$789,172CLTR
20232/2 Multi-Center CLEAN AIR 2 Randomized Control Trial in COPD1U24HL169566-01 · under PAR-22-193EHRHARDT, STEPHANJOHNS HOPKINS UNIVERSITY, MD$658,544CLTR
20232/2: Pediatric Prehospital Airway Resuscitation Trial (Pedi-PART)1U24HL165014-01A1 · under PAR-22-193VANBUREN, JOHNUNIVERSITY OF UTAH, UT$561,767CLTR
20232/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial1U24HL161359-01A1 · under PAR-19-330KING, WENDY CWISNIEWSKI, STEPHEN RUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$445,858ZHL1
20222/2 REACT-AF: Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation1U24HL165066-01 · under PAR-19-330HANLEY, DANIEL FTHOMPSON, RICHARDYENOKYAN, GAYANEJOHNS HOPKINS UNIVERSITY, MD$1,839,921CLTR
20221/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia1U24HL157560-01A1 · under PAR-19-330SHAW, BRONWENMEDICAL COLLEGE OF WISCONSIN, WI$1,161,689ZHL1
20222/2 Trauma Resuscitation with Group O Whole Blood or Products (TROOP)1U24HL157310-01A1 · under PAR-19-330DESANTIS, STACIAUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX$653,807CLTR
20222/2 Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT Trial) –DCC1U24HL155811-01A1 · under PAR-19-330TARPEY, THADDEUSTROXEL, ANDREA BNEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY$622,751CLTR
20222/2 Percutaneous Intervention Versus Observational Trial of Arterial ductus management in Low-weight infants (PIVOTAL) Data Coordinating Center1U24HL161360-01 · under PAR-19-330KING, WENDY CWISNIEWSKI, STEPHEN RUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$447,190ZHL1
20212/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC1U24HL151457-01A1 · under PAR-19-330CHAKRABORTY, HRISHIKESHYENOKYAN, GAYANEZIMMERMAN, KANECIA OBIEDUKE UNIVERSITY, NC$935,417ZHL1
20212/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial1U24HL154946-01A1 · under PAR-19-330SPINO, CATHERINE AUNIVERSITY OF MICHIGAN AT ANN ARBOR, MI$863,939CLTR
20212/2 Pediatric Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)1U24HL159132-01 · under PAR-19-330YEATTS, SHARON DZIUBAMEDICAL UNIVERSITY OF SOUTH CAROLINA, SC$660,295CLTR
20212/2 The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial1U24HL152304-01A1 · under PAR-19-330RATCLIFFE, SARAH JUNIVERSITY OF VIRGINIA, VA$544,353CLTR
20212/2, Data Coordinating Center for the Long-term Effectiveness of the Anti-obesity medication Phentermine: the LEAP Trial1U24HL155802-01A1 · under PAR-19-330PAJEWSKI, NICHOLAS M.WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC$449,621CLTR
2021(2/2) Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)1U24HL153846-01A1 · under PAR-19-330ABEBE, KALEAB ZUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$391,605CLTR
20212/2 Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease (Tele-COPD)1U24HL155807-01A1 · under PAR-19-330ABAN, INMACULADAUNIVERSITY OF ALABAMA AT BIRMINGHAM, AL$360,392CLTR
20202/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)1U24HL147018-01A1 · under PAR-18-410CASPER, THERON CUNIVERSITY OF UTAH, UT$906,728ZHL1
2020RACE-CARS DCC 2/21U24HL146938-01A1 · under PAR-18-410AL-KHALIDI, HUSSEINMARK, DANIEL BDUKE UNIVERSITY, NC$697,029CLTR
20202/2: Sickle Cell Disease Treatment with Arginine Therapy (STArT) trial1U24HL148563-01A1 · under PAR-18-410CASPER, THERON CUNIVERSITY OF UTAH, UT$659,657ZHL1
20202/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis1U24HL147012-01A1 · under PAR-18-410CHEN, YING QINGHUANG, YINGFRED HUTCHINSON CANCER RESEARCH CENTER, WA$508,756CLTR
2020(2/2) Log2Lose: Incenting Weight Loss and Dietary Self-Monitoring in Real Time to Improve Weight Management1U24HL150227-01A1 · under PAR-19-330PENDERGAST, JANE FSHAW, RYAN JEFFREYDUKE UNIVERSITY, NC$414,768CLTR
2020The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)1U24HL148316-01A1 · under PAR-19-330DAVIS, BARRY RUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX$335,707CLTR
20192/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)1U24HL143217-01A1 · under PAR-18-410BROOKS, MARIA MORIUNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA$994,923ZHL1
20192/2 ICECAP: Influence of Cooling duration on Efficacy in Cardiac Arrest Patients1U24HL145272-01A1 · under PAR-18-410RAMAKRISHNAN, VISWANATHANYEATTS, SHARON DZIUBAMEDICAL UNIVERSITY OF SOUTH CAROLINA, SC$593,402CLTR
2019Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study1U24HL145265-01A1 · under PAR-18-410FLAHERTY, KEVIN RSPINO, CATHERINE AUNIVERSITY OF MICHIGAN AT ANN ARBOR, MI$582,305CLTR
20192/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT) Bleeding Data Coordinating Center1U24HL140090-01A1 · under PAR-18-410CATELLIER, DIANE JRESEARCH TRIANGLE INSTITUTE, NC$527,881CLTR
20192/2: An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study.1U24HL140109-01A1 · under PAR-18-410PARKER, ROBERT A.MASSACHUSETTS GENERAL HOSPITAL, MA$488,203CLTR
20192/1 Arrest Respiratory Failure due to Pneumonia (ARREST PNEUMONIA)1U24HL141727-01A1 · under PAR-18-410DESAI, MANISHASTANFORD UNIVERSITY, CA$377,990CLTR
20192/2 PROmote weight loss in obese PAD patients to preVEnt mobility loss: The PROVE Trial--DCC1U24HL141732-01A1 · under PAR-18-410AMBROSIUS, WALTER TWAKE FOREST UNIVERSITY HEALTH SCIENCES, NC$221,385CLTR
20182/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE)1U24HL137907-01A1 · under PAR-16-301BARNHART, HUIMAN XDUKE UNIVERSITY, NC$1,333,276CLTR
2018Transfusion of Prematurity Early School Age Follow-up (TOP 5) DCC1U24HL143216-01 · under PAR-16-301DAS, ABHIKRESEARCH TRIANGLE INSTITUTE, NC$1,298,791CLTR
20182/2: A Randomized Controlled Trial of Pravastatin for the Prevention of Preeclampsia in High Risk Women1U24HL140168-01 · under PAR-16-301CLIFTON, REBECCA GERSNOVIEZTHOM, ELIZABETH ANNGEORGE WASHINGTON UNIVERSITY, DC$1,091,697CLTR
2018Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea - DCC1U24HL140412-01 · under PAR-16-301REDLINE, SUSAN S.WANG, RUIBRIGHAM AND WOMEN'S HOSPITAL, MA$896,611CLTR
20182/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (DCC)1U24HL141723-01 · under PAR-16-301WYPIJ, DAVIDBOSTON CHILDREN'S HOSPITAL, MA$812,214ZHL1
20172/2 Hydrocortisone for BPD Respiratory and Developmental Outcomes Study (HYBRiD Outcomes Study): Data Coordinating Center1U24HL137729-01 · under PAR-16-301DAS, ABHIKRESEARCH TRIANGLE INSTITUTE, NC$487,278CLTR
20172/2 Catheter-Directed Therapy for Chronic DVT (C-TRACT Trial)-DCC1U24HL137835-01 · under PAR-16-301KEARON, CLIVEMCMASTER UNIVERSITY, ON$340,481CLTR

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) | ScienceDex | ConductScience